サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1292926

慢性腰痛（CLBP）治療の世界市場2023-2030

Global Chronic Low Back Pain (CLBP) Treatment Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 160 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
慢性腰痛（CLBP）治療の世界市場2023-2030
出版日: 2023年05月22日
発行: Orion Market Research
ページ情報: 英文 160 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

慢性腰痛（CLBP）治療市場は、予測期間中にCAGR 4.8%の大幅な成長が見込まれています。CLBPは世界的に重要な健康問題であり、その蔓延に寄与している数多くの主要因があります。主な要因には、肥満、傷害、職業上の危険、心理学的障害、遺伝的障害などがあり、CLBPの世界の増加を牽引しています。

しかし、CLBP治療の重大な副作用とCLBPの発生と合併症に関する過失は、オピオイドの過剰乱用のために、市場の収益成長を制限する可能性があります。米国立薬物乱用研究所（NIDA）によると、慢性疼痛のためにオピオイドを処方された患者の約21～29％が誤用し、最大12％がオピオイド使用障害を発症しています。さらにNIDAは、オピオイド過剰摂取による死亡者数は1999年以来5倍以上に増加しており、2019年だけでも米国では49,000人以上のオピオイド関連過剰摂取による死亡者が出ているとしています。

しかし、慢性腰痛薬のメーカーにとってはチャンスでもあります。処方されたオピオイドを誤用し、オピオイド使用障害を発症する人の割合がこれほど多いことから、慢性疼痛管理のための代替治療の選択肢が明らかに必要とされています。このことは、メーカーにとって、中毒や誤用のリスクを伴わずに慢性腰痛を効果的に管理できる非オピオイド薬を開発・製造する機会を提供することになります。この重要な要件に取り組むことで、メーカーは慢性疼痛に苦しむ人々の生活を改善できるだけでなく、オピオイドの蔓延対策にも貢献できます。例えば、2020年12月にFDAから承認されたメロキシカムの新剤形（Qmiiz ODT）は、ルピン社が製造する非ステロイド性抗炎症薬です。これは口腔内崩壊錠で、水を必要とせず口腔内で速やかに溶解します。

セグメント別の展望

オンライン市場が大きなシェアを占めると予想されます。eコマースプラットフォームの成長とインターネット普及率の向上により、医薬品業界ではオンライン販売が急増しています。これにより、様々なオンライン薬局が処方箋薬の迅速なデリバリーを提供する道が開かれました。例えば、Walgreensは2020年11月、米国内の市場全域で24時間年中無休の即日配達サービスを拡大しました。さらに、最短1時間での当日配達に加え、店内、ドライブスルー、カーブサイドでの最短30分での受け取りを開始しました。顧客体験を向上させる継続的な努力の一環として、Walgreensは現在、ニューメキシコ州、オクラホマ州、および一部のテキサス州の市場で30分以内の受け取り保証を試験的に実施しており、注文した商品が30分以内に受け取れない場合、買い物客のバスケットの費用を負担します。

地域別展望

北米地域が世界の慢性腰痛（CLBP）治療市場をリード

北米地域が同市場において突出したシェアを占めると予想されています。成長の主な要因は、高齢化、座りがちなライフスタイル、肥満や慢性疾患などの健康関連問題の増加です。また、健康インフラを強化するための政府による投資の増加は、CLBP治療市場の需要を促進すると予想されています。例えば、米国は2021年にヘルスケアに4兆2,550億米ドルを費やしており、これには医師サービス、処方薬、その他の個人的なヘルスケア費用が含まれます。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Endo Pharmaceuticals Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Johnson & Johnson Services Inc.
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Koninklijke Philips N.V.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Pfizer Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Sanofi S.A.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 慢性腰痛症（CLBP）治療の世界市場：治療タイプ別
    • 鎮痛薬
    • 非ステロイド性抗炎症薬（NSAIDs）
    • 抗痙攣薬
    • 抗うつ薬
    • その他（筋弛緩薬）
  • 慢性腰痛症（CLBP）治療の世界市場：流通チャネル別
    • オンライン
    • オフライン
  • 慢性腰痛症（CLBP）治療の世界市場：エンドユーザー別
    • 病院
    • 整形外科クリニック
    • 外来手術センター
    • その他（教育機関）

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Abbott Laboratories
  • Actiza Pharmaceuticals Pvt. Ltd.
  • AstraZeneca PLC
  • Becton, Dickinson, and Co.
  • Bio Wave Corp.
  • Boston Scientific Corp.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Endo Pharmaceuticals Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Service Inc.
  • Koninklijke Philips N.V.
  • Lupin ltd.
  • Medtronic plc
  • Merck & Co., Inc.,
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceuticals
  • Vertebral Technologies Inc.
図表

LIST OF TABLES

  • 1. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL ANALGESIC MEDICATIONS FOR CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) FOR CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 4. GLOBAL ANTICONVULSANTS FOR CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 5. GLOBAL ANTIDEPRESSANTS FOR CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 6. GLOBAL OTHER TREATMENT TYPES FOR CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 7. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 8. GLOBAL ONLINE CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL OFFLINE CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 11. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT IN ORTHOPEDIC CLINIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT IN AMBULATORY SURGERY CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT IN OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 20. EUROPEAN CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 22. EUROPEAN CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 23. EUROPEAN CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 24. ASIA-PACIFIC CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. ASIA-PACIFIC CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 27. ASIA-PACIFIC CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SHARE BY TREATMENT TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL ANALGESIC MEDICATIONS FOR CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL ANTICONVULSANTS FOR CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) FOR CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL ANTIDEPRESSANTS FOR CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL OTHER TREATMENT TYPES FOR CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SHARE BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • 8. GLOBAL ONLINE CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL OFFLINE CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SHARE BY END-USER, 2022 VS 2030 (%)
  • 11. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT IN HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT IN ORTHOPEDIC CLINIC MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT IN AMBULATORY SURGERY CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT IN OTHER MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. US CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CANADA CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. UK CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. FRANCE CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. ITALY CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SPAIN CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF EUROPE CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. INDIA CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. CHINA CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)

26. JAPAN CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SIZE, 2022-2030( $ MILLION)

  • 27. SOUTH KOREA CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CHRONIC LOW BACK PAIN (CLBP) TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027308

Global Chronic Low Back Pain (CLBP) Treatment Market Size, Share & Trends Analysis Report by Treatment Type (Analgesic Medications, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Anticonvulsants, Antidepressants, and Others), by Distribution Channel (Online and Offline), and by End-User (Hospitals, Orthopedic Clinic, Ambulatory Surgery Centers, and Others) Forecast Period (2023-2030)

The CLBP treatment market is anticipated to grow at a considerable CAGR of 4.8% during the forecast period. CLBP is a significant health issue globally, with numerous key drivers contributing to its prevalence. Some of the key factors includes obesity, injury, occupational hazards, psychological and genetic disorders are driving the CLBP instances globally.

However, the serious adverse effects of CLBP medications and negligence regarding the occurrence and complications of CLBP may limit the revenue growth of the market, owing to the excessive abuse of opioid. According to the National Institute on Drug Abuse (NIDA), approximately 21 to 29% of patients who are prescribed opioids for chronic pain misuse them, and up to 12% develop an opioid use disorder. Furthermore, NIDA states that opioid overdose deaths have increased by over five times since 1999, and in 2019 alone, there were over 49,000 opioid-related overdose deaths in the US.

However, it also presents an opportunity for manufacturers of chronic low back pain medications. With such a significant percentage of individuals misusing their prescribed opioids and developing opioid use disorder, there is a clear need for alternative treatment options for chronic pain management. This presents an opportunity for manufacturers to develop and produce non-opioid medications that can effectively manage chronic low back pain without the risk of addiction or misuse. By addressing this critical requirement, manufacturers can not only improve the lives of those suffering from chronic pain but also contribute to combatting the opioid epidemic. For instance, in December 2020, a new formulation of meloxicam (Qmiiz ODT) was approved by the FDA, is an NSAIDs manufactured by Lupin Ltd. This is an orally disintegrating tablet that rapidly dissolves in the mouth without the required water.

Segmental Outlook

The chronic low back pain treatment market is segmented based on treatment type, distribution channels, and end-user. Based on treatment type, the market is sub-segmented into analgesic medications, NSAIDs, anticonvulsants, antidepressants, and other medications such as muscle relaxants (cyclobenzaprine and tizanidine) that can reduce muscle spasms and tension. Based on the distribution channel, the market is categorized into online and offline. Based on distribution channel market is sub segmented into hospitals, orthopedic clinic, ambulatory surgery centers, and others (educational institution). Among these,

The online sub-segment is expected to cater to a prominent share of the market. The growth of e-commerce platforms and the increasing internet penetration has led to a surge in online sales in the pharmaceutical industry. This has paved the way for various online pharmacies to offer rapid delivery of prescription drugs. For instance, in November 2020, Walgreens extended its Same Day Delivery service to operate 24 hours a day, seven days a week across markets in the US. In addition, the company has launched Pickup in as little as 30 minutes in-store, via drive-thru and curbside, along with same day delivery in as little as one hour. As part of its continued efforts to enhance the customer experience, Walgreens is currently piloting a 30-Minute Pickup Guarantee in New Mexico, Oklahoma, and select Texas markets, covering the cost of shoppers' baskets if the order is not ready for pickup within 30 minutes.

Regional Outlooks

The global chronic low back pain (CLBP) treatment market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). The North America region is anticipated to witness considerable growth in the market. Increasing funding by regulatory bodies for the healthcare sector and advanced healthcare infrastructure is driving market growth. For instance, as per the report by the American Chiropractic Association, US spends approximately $50 billion each year on healthcare for low-back pain.

Global Chronic Low Back Pain (CLBP) Treatment Market Growth, by Region 2023-2030

Source: OMR Analysis

The North America Region Leads in the Global Chronic Low Back Pain (CLBP) Treatment Market

The North America region is anticipated to hold a prominent market share in the market. The growth is mainly attributed to aging population, sedentary lifestyles, and increasing health-related problems such as obesity and chronic diseases. Also, the growing investment by the government to strengthen the health infrastructure is anticipated to propel the demand for the CLBP treatment market. For instance, the US spent $4,255 billion on health care in 2021 which include Physician services, Prescription drugs and other personal health care costs.

Market Players Outlook

The chronic low back pain treatment market is a highly competitive arena, with several major players are focused on developing innovative strategies to differentiate themselves from their competitors and gain a larger share of the market. Johnson & Johnson Services Inc, Pfizer Inc., Sanofi S.A., Endo Pharmaceuticals Inc., and Koninklijke Philips N.V. are some of the players in this market. These companies are continuously improving the performance of chronic low back pain treatment by investing in research and development, as well as through strategic partnerships and acquisitions. For instance, in February 2021, Mesoblast ltd. Announced positive results from a Phase 3 trial of its allogeneic cellular therapy rexlemestrocel-L for chronic low back pain due to degenerative disc disease. The trial enrolled 404 patients who were refractory to conventional treatments, and the results showed that a single injection of the therapy may provide a safe and effective opioid-sparing treatment.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the chronic low back pain (CLBP) treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Endo Pharmaceuticals Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Johnson & Johnson Services Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Koninklijke Philips N.V.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Pfizer Inc.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Sanofi S.A.
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Chronic Low Back Pain (CLBP) Treatment Market by Treatment Type
    • 4.1.1. Analgesic Medications
    • 4.1.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 4.1.3. Anticonvulsants
    • 4.1.4. Antidepressants
    • 4.1.5. Others (Muscle Relaxants)
  • 4.2. Global Chronic Low Back Pain (CLBP)Treatment Market by Distribution Channel
    • 4.2.1. Online
    • 4.2.2. Offline
  • 4.3. Global Chronic Low Back Pain (CLBP)Treatment Market by End-User
    • 4.3.1. Hospitals
    • 4.3.2. Orthopedic Clinic
    • 4.3.3. Ambulatory Surgery Centers
    • 4.3.4. Others (Educational institution)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Abbott Laboratories
  • 6.2. Actiza Pharmaceuticals Pvt. Ltd.
  • 6.3. AstraZeneca PLC
  • 6.4. Becton, Dickinson, and Co.
  • 6.5. Bio Wave Corp.
  • 6.6. Boston Scientific Corp.
  • 6.7. Bristol-Myers Squibb Co.
  • 6.8. Eli Lilly and Co.
  • 6.9. Endo Pharmaceuticals Inc.
  • 6.10. GlaxoSmithKline plc
  • 6.11. Johnson & Johnson Service Inc.
  • 6.12. Koninklijke Philips N.V.
  • 6.13. Lupin ltd.
  • 6.14. Medtronic plc
  • 6.15. Merck & Co., Inc.,
  • 6.16. Novartis AG
  • 6.17. Pfizer, Inc.
  • 6.18. Sanofi S.A.
  • 6.19. Takeda Pharmaceuticals
  • 6.20. Vertebral Technologies Inc.